Logo

Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Share this
Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Shots:

  • The approval is based on P-III ASPECT-NP study results assessing Zerbaxa (3gm- IV every 8hrs.) vs meropenem (1gm- IV- every 8hrs.) in 726 patients with HABP/VABP on mechanical ventilation aged ≥18yrs.
  • The P-III ASPECT-NP study results demonstrated that Zerbaxa is superior to meropenem for 28-day all-cause mortality (24% vs 25.3%)- clinical response at Test-of-Cure (54.4% vs 53.3%)
  • Zerbaxa is a combination therapy of anti-bacterial & beta-lactamase inhibitor- act by reducing the development of drug-resistant bacteria and has received FDA’s Priority Review designation for preventing infection by susceptible Gram-negative microorganisms

Ref: Merck | Image: Merck

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions